Christian Hinrichs, PhD. (Rutgers Cancer Institute)

Christian Hinrichs, PhD. (Rutgers Cancer Institute)

Butler Seminar Series

Event Date/Location

March 23, 2022 - 12:00 pm to 1:00 pm
Thomas Laboratory 003 or via Zoom


  • Christian Hinrichs Photo

    Christian Hinrichs

    Chief of the Section of Cancer Immunotherapy
    Co-Director of the Duncan and Nancy MacMillan Cancer Immunology and Metabolism Center of Excellence
    Rutgers Cancer Center

    Christian S. Hinrichs, MD, joins Rutgers Cancer Institute as Chief of the Section of Cancer Immunotherapy and Co-Director of the Duncan and Nancy MacMillan Cancer Immunology and Metabolism Center of Excellence following his tenure at the National Institutes of Health (NIH). Dr. Hinrichs is a tenured Professor of Medicine at the Rutgers Robert Wood Johnson Medical School, and holds the position of Program Co-leader of the Cancer Metabolism and Growth Program.

    Having earned a bachelor’s degree and medical degree from the University of Missouri – Kansas City (UMKC) in a combined degree program, Hinrichs also received surgical training at UMKC and surgical oncology training at Roswell Park Comprehensive Cancer Center. He completed fellowships in surgical oncology, medical oncology, and immunotherapy and tumor immunology at the National Cancer Institute, as well as a residency in internal medicine at George Washington University School of Medicine and Health Sciences. 

    Dr. Hinrichs conducts basic research and clinical research to develop T-cell therapies for HPV-associated cancers and other epithelial malignancies.


Engineered T Cell Therapy for Viral and Non-viral Epithelial Cancers

Engineered T cell therapy has demonstrated high response rates and frequent complete responses in hematologic malignancies and holds promise for the treatment of wide-ranging cancers. Relative to hematologic cancers, progress in solid tumors, and especially in common epithelial cancers, has been more measured. However, recent clinical trials have established clear proof of principle for the approach, with two T cell receptor (TCR) gene-engineered T cell approaches demonstrating safety and clinical activity in HPV-associated epithelial cancers. A recent trial, targeting the E7 antigen, showed robust tumor regression in highly refractory cancers including cervical cancer, vulvar cancer, anal cancer, and oropharyngeal cancer and tumors that were resistant to PD1-based therapies. These and other studies in a range of malignancies are guiding expanded application of engineered T cell therapy and the development of next-generation technologies.




Hybrid Seminar - open to those participating in the Princeton Asymptomatic Testing Program


Hosted by Yibin Kang, Molecular Biology Dept.